N-Boc-4-哌啶酮-3-甲酸甲酯 | 161491-24-3

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-Boc-4-哌啶酮-3-甲酸甲酯
• 中文别名: 1-叔丁氧羰基-3-甲酸甲酯-4-哌啶酮；4-氧代哌啶-1,3-二甲酸1-叔丁酯3-甲酯；N-BOC-4-氧代哌啶-3-甲酸甲酯(P4M)；N-BOC-4-氧代哌啶-3-甲酸甲酯；N-BOC-4-哌啶酮-3-甲酸甲酯盐酸盐,N-BOC-3-甲氧羰基-4-哌啶酮盐酸盐；4-氧代哌啶-1,3-二甲酸-1-叔丁酯-3-甲酯；N-BOC-4-哌啶酮-3-甲酸甲酯；4-氧代哌啶-1,3-二甲酸 1-叔丁酯 3-甲酯
• 英文名称: methyl 1-tert-butoxycarbonyl-4-oxo-3-piperidinecarboxylate
• 英文别名: 4-Oxo-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester；tert-butyl-3-methyl-4-hydroxy-5,6-dihydropyridine-1,3-(2H)-dicarboxylate；4-oxopiperidine-1,3-dicarboxylic acid 1-t-butyl ester 3-methyl ester；methyl 1-tert-butoxycarbonyl-4-oxo-3-piperidine carboxylate；methyl N-tert-butoxycarbonyl-4-oxopiperidine-3-carboxylate；1-tert-Butyl 3-methyl 4-oxopiperidine-1,3-dicarboxylate；1-O-tert-butyl 3-O-methyl 4-oxopiperidine-1,3-dicarboxylate
• CAS: 161491-24-3
• 化学式: C₁₂H₁₉NO₅
• 分子量: 257.287
• InChiKey: HBWUTYLVFYVXML-UHFFFAOYSA-N

物化性质

• 熔点：
  32-34 °C
• 沸点：
  350.0±42.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  存放于惰性气体中，避免与空气接触。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 1-BOC-4-oxopiperidine-3-carboxylate
Synonyms: 1-tert-Butyl 3-methyl 4-oxopiperidine-1,3-dicarboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 1-BOC-4-oxopiperidine-3-carboxylate
CAS number: 161491-24-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H19NO5
Molecular weight: 257.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

4-氧代哌啶-1,3-二甲酸1-叔丁酯3-甲酯可作为有机合成中间体和医药中间体，在实验室研发及化工医药合成过程中均有广泛应用。

反应信息

• 作为反应物：
  描述：

  N-Boc-4-哌啶酮-3-甲酸甲酯 在 四(三苯基膦)钯 、 碳酸氢钠 、 三乙胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 水 、 甲苯 、 乙腈 为溶剂， 反应 34.33h， 生成
  参考文献：
  名称：

  铜催化的N-甲苯磺酰hydr生成α-烷氧基环烯酮

  摘要：

  20 mol％的碘化亚铜和叔丁醇锂的组合会触发从很容易获得的N-甲苯磺酰azo生成大量取代的，官能化的α-烷氧基2 H-萘烯酮。数据表明，这种转变是通过类铜环铜与酯的环加成反应发生的，然后是路易斯酸催化的原位生成的烷氧基环氧中间体的[1,2]烷基转移。

  DOI：

  10.1002/anie.201505993
• 作为产物：
  描述：

  1-苄基-3-甲氧羰基-4-哌啶酮盐酸盐 在 palladium 10% on activated carbon 、 氢气 、 溶剂黄146 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 31.0h， 生成 N-Boc-4-哌啶酮-3-甲酸甲酯
  参考文献：
  名称：

  非对映会聚钴催化芳基化全合成 (±)-帕罗西汀

  摘要：

  报道了帕罗西汀的全合成，其中涉及 3-取代 4-溴-N-Boc-哌啶（Boc = 叔丁氧羰基）底物的非对映选择性和非对映会聚钴催化 sp3-sp2 偶联反应作为关键步骤。获得了 9:1 的非对映选择性，而涉及构象锁定的 3-取代 4-溴-叔丁基环己烷环的对照实验则以基本上完​​全的立体选择性进行。

  DOI：

  10.1002/ejoc.201402108

文献信息

• Piperdine derivatives useful as CCR3 antagonists
  申请人：Ting C. Pauline

  公开号：US20050182095A1

  公开（公告）日：2005-08-18

  The use of CCR3 antagonists of the formula I or a pharmaceutically acceptable salt thereof for the treatment of asthma is disclosed, as well as novel compounds of the formula II, pharmaceutical compositions comprising them, and their use in the treatment of asthma, wherein R, R a , X, X a , R 1 , R 2 , R 2a , R 14 , R 14a , R 16 and n are as defined in the specification.

  公开了使用公式I的CCR3拮抗剂或其药用盐治疗哮喘，以及公式II的新化合物、包含它们的药物组合物，以及它们在治疗哮喘中的应用，其中R、Ra、X、Xa、R1、R2、R2a、R14、R14a、R16和n的定义如规范中所述。
• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20160031908A1

  公开（公告）日：2016-02-04

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

  揭示了新颖的化合物以及治疗与异常白细胞召集和/或激活相关的疾病的方法。该方法包括向需要的受试者施用代表的化合物的有效量： 或其生理上可接受的盐。
• [EN] HISTONE METHYLTRANSFERASE INHIBITORS<br/>[FR] INHIBITEURS DE L'HISTONE MÉTHYLTRANSFÉRASE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2018119208A1

  公开（公告）日：2018-06-28

  The present disclosure provides certain angular tricyclic compounds that are histone methyltransi erases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies (e.g., beta- thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本公开提供了一些角三环化合物，这些化合物是组蛋白甲基转移酶G9a和/或GLP的抑制剂，因此可用于治疗可以通过抑制G9a和/或GLP来治疗的疾病，例如癌症和血红蛋白病（例如，β-地中海贫血和镰状细胞病）。还提供了含有这些化合物的药物组合物以及制备这些化合物的方法。
• [EN] MODULATORS OF AMYLOID BETA.<br/>[FR] MODULATEURS DE LA PROTÉINE ?-AMYLOÏDE
  申请人：ASTRAZENECA AB

  公开号：WO2010053438A1

  公开（公告）日：2010-05-14

  The present invention relates to novel compounds of formula I and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as therapeutic methods for treatment and/or prevention of various diseases. In particular the invention relates to compounds, which inhibit the Aβ40 and Aβ42 production, increase the Aβ37 and Aβ38 production and maintain the Notch signaling and will be used for treatment and/or prevention of Aβ-related pathologies such as Alzheimer's disease, Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及式I的新化合物及其治疗上可接受的盐，它们的药物组合物，制造它们的方法以及它们作为治疗和/或预防各种疾病的治疗方法的使用。特别是，本发明涉及抑制Aβ40和Aβ42产生，增加Aβ37和Aβ38产生并维持Notch信号传导的化合物，并将用于治疗和/或预防与Aβ相关的病理，如阿尔茨海默病、唐氏综合症和β-淀粉样蛋白血管病，例如但不限于脑淀粉样血管病、遗传性脑出血、与认知障碍相关的疾病，例如但不限于MCI（“轻度认知障碍”）、阿尔茨海默病、记忆丧失、与阿尔茨海默病相关的注意力缺陷症状、与阿尔茨海默病或包括混合血管和退行性来源的痴呆在内的疾病相关的神经退行性变、早老性痴呆、老年性痴呆和与帕金森病、进行性核上瘫或皮层基底退行性变相关的痴呆。
• CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF
  申请人：FLX Bio, Inc.

  公开号：US20180072743A1

  公开（公告）日：2018-03-15

  Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of chemokine receptor activity.

  披露的内容包括但不限于，用于调节趋化因子受体活性的化合物及其使用方法。